Výsledky vyhledávání - "Victor G. Gian"

Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures

Autor: John V. Heymach, F. Anthony Greco, Davey B. Daniel, David R. Spigel, David M. Waterhouse, Howard A. Burris, L Finney, Kent C. Shih, Victor G. Gian, John D. Hainsworth, Andrew Lipman

Publikováno v: Cancer. 124:2355-2364

Background This study compared the efficacy and safety of treatment with erlotinib plus pazopanib versus erlotinib plus placebo in patients with previously treated advanced non-small cell lung cancer (NSCLC). Methods Patients with progressive-stage I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f1fe368360818ff4c11c77ffadf6499
https://doi.org/10.1002/cncr.31290

Zobrazit plný text záznamu

Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer

Autor: Jeffrey R. Infante, Lowell L. Hart, F. Anthony Greco, David R. Spigel, Victor G. Gian, Charles D. Webb, Martin J. Bury, David M. Waterhouse, Dianna Shipley, Howard A. Burris, John D. Hainsworth, John D. Zubkus

Publikováno v: Lung Cancer. 78:70-75

Background Epothilones, a new class of cytotoxic agents, have demonstrated activity in non-small-cell lung cancer (NSCLC). This phase II study examined ixabepilone/carboplatin (cohort A) and ixabepilone/carboplatin/bevacizumab (cohort B) as first-lin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc27789f8aa24a0a6d6ffca7e7faa03
https://doi.org/10.1016/j.lungcan.2012.06.008

Zobrazit plný text záznamu

Increasing the percentage of advance directives in patient medical records

Autor: Victor G. Gian, Jan Conwill, Christopher A. Waynick

Publikováno v: Journal of Clinical Oncology. 36:226-226

226 Background: Advance care planning is often initiated too late, which leads to added stress and high resource utilization at the end of life which is contrary to many patients’ wishes. Ideally, discussing patient’s wishes should start early. A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7825fd5955b7ea19c6de1d4281a85b2e
https://doi.org/10.1200/jco.2018.36.30_suppl.226

Zobrazit plný text záznamu

A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer

Autor: Elizabeth R. Vazquez, F. Anthony Greco, Jitendra G. Gandhi, Suzanne F. Jones, John D. Hainsworth, Bobby L. Clark, James D. Peyton, Victor G. Gian, Kimberly West-Osterfield, Howard A. Burris, David R. Spigel

Publikováno v: Journal of Thoracic Oncology. 5(6):862-866

Background Carboplatin and topotecan are commonly used in the treatment of small cell lung cancer (SCLC); however, there are no data for this combination in the first-line setting using weekly topotecan. In this multicenter, community-based phase II

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96ba74af6eb6274a2feecee4750f1d6

Zobrazit plný text záznamu

A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Autor: Victor G. Gian, Mark Moskowitz, Ahmed Zakari, Chris Earwood, Ralph V. Boccia, Richard LoCicero, David M. Waterhouse, Andrew Lipman, Johanna C. Bendell, A. A. Meluch, Cassie M. Lane, James D. Peyton

Publikováno v: The Oncologist

Lessons Learned This regimen is a viable option for patients with liver-only metastatic colorectal cancer. Enrollment criteria for future studies should include testing for the newly identified KRAS mutations. Background. Patients with liver-only met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dd8bb578a8d2abed1e310c9625b1b15
https://pubmed.ncbi.nlm.nih.gov/26911408

Zobrazit plný text záznamu

Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

Autor: John D. Hainsworth, Victor G. Gian, D. S. Thompson, John A. Bismayer, Robert C. Whorf, William M. Merritt, B. Stephens Dudley, L Finney

Publikováno v: Cancer Medicine

5513 Background: The combination of paclitaxel and carboplatin is the most widely used chemotherapy regimen for patients (pts) with advanced ovarian cancer, producing a median survival of approximately 36 months. Recently, the addition of bevacizumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af2d4c011c17ee9696034844e6f2c370
https://pubmed.ncbi.nlm.nih.gov/25556916

Zobrazit plný text záznamu

A Phase I trial of protracted oral fixed-dose temozolomide

Autor: F. Anthony Greco, Noel T. Willcutt, Eric L. Raefsky, Aurelia F. Beschorner, Howard A. Burris, Suzanne F. Jones, Fernando T. Miranda, Victor G. Gian, Glyndon Kennerly, John D. Hainsworth

Publikováno v: Cancer. 104(9)

BACKGROUND The current Phase I trial was conducted to determine the dose-limiting toxicity (DLT), maximum tolerated dose, and recommended Phase II dose of oral fixed-dose temozolomide when administered for 5 of every 7 days on a continuous basis. MET

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd6916a209e973d4a48663865509ea50
https://pubmed.ncbi.nlm.nih.gov/16134182

Zobrazit plný text záznamu

Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients

Autor: Lester L. Porter, Suzanne F. Jones, M. Thomas, Victor G. Gian, Mark Mainwaring, F. Anthony Greco, John D. Hainsworth

Publikováno v: Clinical lung cancer. 4(6)

To evaluate the feasibility, toxicity, and efficacy of oral gefitinib (ZD1839, Iressa™) in patients with refractory non—small-cell lung cancer (NSCLC) treated in a community-based setting. One hundred twenty-four patients with advanced, refractor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a4fdeb717034f3f7201694dd9b5af56
https://pubmed.ncbi.nlm.nih.gov/14599303

Zobrazit plný text záznamu

Phase I. Trial of irinotecan and temozolomide in patients with solid tumors

Autor: Suzanne F, Jones, Victor G, Gian, F Anthony, Greco, Fernando T, Miranda, Dianna L, Shipley, Dana S, Thompson, John D, Hainsworth, Mitchell A, Toomey, Noel T, Willcutt, Howard A, Burris

Publikováno v: Oncology (Williston Park, N.Y.). 17(5 Suppl 5)

This phase I study was conducted to determine the dose-limiting toxicity, maximum tolerated doses, and recommended phase II doses of the combination of irinotecan (CPT-11, Camptosar) and temozolomide (Temodar). Patients have received irinotecan and t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9708a8fff18b09c34943b9e7b8f93ccb
https://pubmed.ncbi.nlm.nih.gov/12800606

Zobrazit plný text záznamu

Phase II study of FOLFOXIRI plus panitumumab (pmab) followed by evaluation for resection, in patients (pts) with metastatic KRAS wild-type colorectal cancer (mCRC) with liver metastases only

Autor: Andrew Lipman, Ralph V. Boccia, Suzanne F. Jones, Johanna C. Bendell, Ahmed Zakari, J. D. Peyton, Victor G. Gian, Anthony Alan Meluch, David Michael Waterhouse

Publikováno v: Journal of Clinical Oncology. 32:e14552-e14552

e14552 Background: Pts with liver-only mCRC who are not candidates for potentially curative resection may be converted to resectable with more aggressive chemotherapy regimens with higher response rates (RR). FOLFOXIRI has shown a higher RR and pts s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8350293f1d9b869088b4e5989c72e7af
https://doi.org/10.1200/jco.2014.32.15_suppl.e14552

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání